Partnership to offer producers genetic analysis of psychedelic mushrooms, cannabis

As demand continues to grow for healthier, more effective alternatives to traditional medicines the Delic Labs-GT Research partnership will offer Canadian producers ‘new, best-in-class products to serve their markets,’ says Delic Labs co-founder Dr. Markus Roggen.

Vancouver-based Delic Labs and GT Research Inc., a leader in applying cutting edge computational and bio-technology to cannabis and psychedelics have announced a partnership that will see Delic Labs offering genetic analysis of psychedelic mushrooms and cannabis to Canadian producers, including detailed analyses of specific areas of the genome relating to traits of highest commercial interest.

The analytical services will include sample preparation, DNA extraction, whole-genome sequencing, computational analysis and reporting.

A federally authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development, Delic Labs serves as the science engine for the Delic platform, conducting research and developing innovative product lines and intellectual property, including psilocybin vaporization technology for future distribution across the Delic’s physical footprint and licensed psychedelic wellness clinics in the United States.

“Partnering with GTR will give us the most comprehensive genomic insights in the industry and build on our efforts to provide the highest standards and quality control for psychedelic and cannabis compounds,” said Dr. Markus Roggen, co-founder of Delic Labs. “As demand continues to grow for healthier, more effective alternatives to traditional medicines, our combined knowledge will offer producers new, best-in-class products to serve their markets.”

Added Delic CEO and co-founder Matt Stang, “Delic is committed to researching and identifying the safest, highest quality psychedelic compounds for commercial use and we look forward to a productive collaboration with our team at Delic Labs.”

Based at the University of British Columbia in Vancouver, and founded by Dr. Roggen, an award-winning chemist, and UBC Professor Dr. Glenn Sammis, Delic Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization. It’s one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. Delic Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world.

READ MORE: Vernon-based magic mushroom company sprouts mental health treatment

Find the latest must-read stories from the cannabis world at, your go-to source for news, trends, products and lifestyle inspiration from the cannabis community and beyond. You can also follow us on Facebook and Instagram and Twitter.